Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials

OR occurred in 38% of sunitinib-treated mRCC patients. Sixty-one percent of responses occurred by 12 weeks of therapy, and responders had favourable pretreatment features and significantly longer survival.